A LinkedIn post from Pulnovo Medical highlights that the company has completed what it describes as its first commercial PADN procedure in Europe, performed in Italy at Azienda Ospedale Università Padova. The procedure followed recent CE-MDR certification and prior market entry in the Middle East, according to the post.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post also notes that the intervention involved collaboration between an Italian interventional cardiology team and a U.S.-based expert proctor. This activity suggests early commercial deployment of Pulnovo’s PADN technology in European real-world settings, which may signal initial revenue-generation opportunities and gradual geographic diversification of its pulmonary hypertension business.
By positioning PADN within CE-MDR-compliant practice and referencing a “globalization strategy,” the post implies ambitions for broader international scaling. For investors, successful early European cases could be an indicator of clinical adoption potential, though the post does not provide quantitative data on pricing, volumes, or reimbursement, leaving overall financial impact and timeline uncertain.